Case Reports and Correspondence

Hung, Po-Cheng; Lin, Pei‐Chin; Tseng, Pi-Lai; Salam, Anooja Abdul; Remadevi, K. S.; Kurup, Renu P; Yadav, Dinesh Kumar; Beniwal, Mukesh Kumar; Jain, Anjali; Aggarwal, Meenakshi; Manchanda, Vikas; Talukdar, B; Krishnan, Janani; Hathiramani, Varun; Hastak, Meenal; Redkar, Rajeev; Roy, Amrita; De, Pranab; Chakraborty, Swapna; Dua, Vivek; Mishra, Devendra; Juneja, Monica; Rathod, Santosh; Tambat, Sejal Bhanudas; Bhad, Roshan; Sagar, Rajesh; Bonciolini, Veronica; Caproni, Marzia; Agarwal, Jaya

doi:10.1007/s13312-013-0158-1

Cited by 7 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, little is known about influenza-associated rhabdomyolysis (IAR). 15 A study showed that influenza viruses account for 42% of all rhabdomyolysis cases. In 300 cases of influenza myositis, 3% was accompanied by rhabdomyolysis.…”

Section: Discussionmentioning

confidence: 99%

Post-influenza aspergillosis, do not underestimate influenza B

Nulens¹,

Bourgeois

2017

IDR

View full text Add to dashboard Cite

Our objective is to highlight and focus on post-influenza aspergillosis, triggered by influenza B virus. This relatively new clinical entity is often associated with a fulminant course of respiratory decline and high mortality. A 51-year immunocompetent woman, without any medical history or risk factors for developing a complicated influenza infection, was admitted to the intensive care unit. During admission, she presented with an afebrile flu-like syndrome, myocarditis, rhabdomyolysis, multiple organ failure, and evolved to severe respiratory distress. The broncho-alveolar lavage contained influenza B RNA, and the culture revealed Aspergillus fumigatus. Despite maximal organ support, immunoglobulin, antiviral and antifungal therapy, the patient died. This case demonstrates that influenza B virus may be life threatening even to immunocompetent adults and may trigger an invasive Aspergillus superinfection.

show abstract

Section: Discussionmentioning

confidence: 99%

Post-influenza aspergillosis, do not underestimate influenza B

Nulens¹,

Bourgeois

2017

IDR

View full text Add to dashboard Cite

show abstract

“…If not treated promptly with corticosteroids or enucleation of the injured eye, blindness can occur in both eyes [65]. Rhabdomyolysis is an acute muscle cell injury caused by various factors such as infections with influenza or measles, physical injuries, and drugs as well as in ARDS [66,67]. Rhabdomyolysis can cause acute kidney injury, disseminated intravascular coagulation (DIC) of the blood, or heart arrhythmia.…”

Section: Histopathologic Findings and Unresolved Issues In Ardsmentioning

confidence: 99%

Pneumonia, Acute Respiratory Distress Syndrome, and Early Immune-Modulator Therapy

Lee

2017

IJMS

115

113

View full text Add to dashboard Cite

Acute respiratory distress syndrome (ARDS) is caused by infectious insults, such as pneumonia from various pathogens or related to other noninfectious events. Clinical and histopathologic characteristics are similar across severely affected patients, suggesting that a common mode of immune reaction may be involved in the immunopathogenesis of ARDS. There may be etiologic substances that have an affinity for respiratory cells and induce lung cell injury in cases of ARDS. These substances originate not only from pathogens, but also from injured host cells. At the molecular level, these substances have various sizes and biochemical characteristics, classifying them as protein substances and non-protein substances. Immune cells and immune proteins may recognize and act on these substances, including pathogenic proteins and peptides, depending upon the size and biochemical properties of the substances (this theory is known as the protein-homeostasis-system hypothesis). The severity or chronicity of ARDS depends on the amount of etiologic substances with corresponding immune reactions, the duration of the appearance of specific immune cells, or the repertoire of specific immune cells that control the substances. Therefore, treatment with early systemic immune modulators (corticosteroids and/or intravenous immunoglobulin) as soon as possible may reduce aberrant immune responses in the potential stage of ARDS.

show abstract